Actively Recruiting
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
Led by China Medical University Hospital · Updated on 2026-03-24
80
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
Sponsors
C
China Medical University Hospital
Lead Sponsor
N
National Health Research Institutes, Taiwan
Collaborating Sponsor
AI-Summary
What this Trial Is About
Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine for clinical symptoms but not cognitive function in the treatment of ultra-resistant schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of ultra-resistant schizophrenia remains unknown.
CONDITIONS
Official Title
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a DSM-5 diagnosis of schizophrenia
- Have been treatment-resistant to at least two antipsychotics before clozapine
- Have been on adequate clozapine treatment for more than 12 weeks without satisfactory response
- Have PANSS total score of 70 or higher and SANS total score of 40 or higher
- Have enough education to communicate effectively and complete study assessments
- Agree to participate and provide informed consent
You will not qualify if you...
- Have a DSM-5 diagnosis of intellectual disability or substance use disorder including alcohol
- History of epilepsy, head trauma, or serious medical or central nervous system diseases other than schizophrenia
- Have clinically significant abnormal laboratory screening tests
- Are pregnant or lactating
- Are unable to follow the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan
Actively Recruiting
Research Team
H
Hsien-Yuan Lane, M.D., Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here